Basel, 09 December 2019 Changes in the Board of Directors and the Corporate Executive Committee of Roche Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that at its December meeting the Board of Directors of Roche Holding Ltd has approved first proposals to the Annual General Meeting on 17 March 2020. Change in the Board... Read more
New extensions on ZEISS Crossbeam 350/550 and ZEISS Atlas 5 improve speed and data quality New technology LaserFIB on ZEISS Crossbeam accelerates FIB-SEM sample preparation. Faster FIB-SEM sample preparation Researchers who perform multi-scale, correlative studies using X-ray microscopy data to drive FIB-SEM site selections today can further enhance their workflows with the newly introduced, patented... Read more
2 December 2019 – Further to the announcement on 19 September, Spectris plc (LSE: SXS), the productivity-enhancing instrumentation and controls company, today announces that it has completed the sale of its BTG Group business to Voith GmbH & Co. KGaA. – ENDS – Contacts: Spectris plcSiobhán Andrews, Head of Corporate Affairs+44 1784 485325 FTI ConsultingRichard... Read more
A brief interview with the president of KERN Precision, Toni Mangold Toni Mangold, President of KERN Precision KERN Microtechnik produces high accuracy milling machines and manufactured parts for customers. With global headquarters in the Bavarian Alps, KERN has set industry-wide standards in high accuracy milling and recently won a Top 100 award for innovative, medium-sized... Read more
13 November 2019 – Spectris plc (‘Spectris’ or the ‘Company’) (LSE: SXS), the productivity-enhancing instrumentation and controls company, announces that it has today published a Notice convening a General Meeting seeking shareholder approval of certain changes to the Remuneration Policy and associated incentive arrangements for the Executive Directors and other senior management of the Company... Read more
Basel, 16 October 2019 Roche reports very strong sales growth in the first nine months of 2019 – outlook raised Group sales increase 10%1 at constant exchange rates and 9% in Swiss francs, due to new products Pharmaceuticals Division sales up 12%, driven by high demand for recently launched medicines, mainly Ocrevus, Hemlibra, Tecentriq and... Read more
Growth Strategy for Analytical & Measuring Instruments Business Read more
Preliminary Q3 2019 sales of about 3% CER growth (vs.~4-5% CER outlook), adjusted EPS in line with outlook Initiatives announced to free up resources to invest in best growth opportunities, in particular new partnership with Illumina in NGS clinical decision-making Venlo, The Netherlands, October 7, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today... Read more
Venlo, The Netherlands, October 07, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announces preliminary sales results for the third quarter of 2019 fall short of expectations. For the third quarter of 2019, QIAGEN currently expects preliminary total net sales growth of about 3% at constant exchange rates (CER) compared to the... Read more